INKINE PHARMACEUTICAL CO INC 4
4 · INKINE PHARMACEUTICAL CO INC · Filed Oct 4, 2005
Insider Transaction Report
Form 4
SCHELLENGER NORMAN D
Director
Transactions
- Disposition to Issuer
Common Stock (right to buy)
2005-09-30−5,000→ 0 totalExercise: $3.92Exp: 2014-08-22→ Common Stock (5,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−30,500→ 0 totalExercise: $2.82Exp: 2013-06-01→ Common Stock (30,500 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−21,000→ 0 totalExercise: $4.20Exp: 2014-06-06→ Common Stock (21,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−51,000→ 0 totalExercise: $2.11Exp: 2015-06-07→ Common Stock (51,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−25,000→ 0 totalExercise: $1.60Exp: 2012-11-10→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 23,015 shares of Salix common stock at a weighted average exercise price of $14.89 per share.